SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES

1 . A method of synthesizing a pharmacological compound substance including the steps of:

attaching a psychoactive base substance to an amino acid; and

creating a prodrug with modified pharmacological behavior.

2 . The method of claim 1 , wherein the psychoactive base substance is made of 3,4-methylenedioxymethamphetamine (MDMA) or an MDMA-like substance chosen from the group consisting of 3,4-methylenedioxamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDEA), 1-(1,3-benzodioxol-5-yl)methyl-2-butanamine (MBDB), 1-(1,3-benzodioxol-5-yl)-2-aminobutane (BDB), methylone, ethylone, 2F-MDA, 5F-MDA, 6F-MDA, 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodo-2-aminoindane (5-IAI), 4-(2-aminopropyl)-benzofuran (4-APB), 5-(2-aminopropyl)-benzofuran (5-APB), 6-(2-aminopropyl)-benzofuran (6-APB), 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine (5-MAPDB), 5-(2-methylaminopropyl)-benzofuran (5-MAPB), mixed dopaminergic-serotonergic amphetamines, N-alkylated analogs of mixed dopaminergic-serotonergic amphetamines, and active metabolites thereof.

3 . The method of claim 1 , wherein the amino acid is chosen from the group consisting of lysine, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.

4 . The method of claim 1 , wherein the prodrug made is lysMDA or lysMDMA.

5 . The method of claim 1 , wherein the amino acid is attached to an amine group of the psychoactive base substance.

6 . The method of claim 1 , wherein the psychoactive base substance is a controlled substance.

7 . The method of claim 1 , wherein said attaching step is further defined as starting synthesis from non-controlled precursors and producing a non-controlled intermediate compound and converting the non-controlled intermediate compound into a psychoactive substance without producing a controlled substance at any step.

8 . The method of claim 7 , wherein said attaching step is further defined as synthesizing the psychoactive base substance from non-controlled precursors and producing a non-controlled compound and converting the non-controlled compound into a psychoactive lysMDMA or lysMDA without producing MDMA or MDA at any step.

9 . The method of claim 1 , wherein said attaching step of the amino acid coupling is further followed by the step of N-diversification (N-alkylation) to derive additional compounds.

10 . The method of claim 1 , wherein the amino acid has an L-configuration.

11 . The method of claim 1 , wherein the amino acid has a D-configuration.

12 . A prodrug made by the method of claim 1 .

13 . The prodrug of claim 12 , wherein the psychoactive base substance is made of 3,4-methylenedioxymethamphetamine (MDMA) or an MDMA-like substance chosen from the group consisting of 3,4-methylenedioxamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDEA), 1-(1,3-benzodioxol-5-yl)methyl-2-butanamine (MBDB), 1-(1,3-benzodioxol-5-yl)-2-aminobutane (BDB), methylone, ethylone, 2F-MDA, 5F-MDA, 6F-MDA, 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodo-2-aminoindane (5-IAI), 4-(2-aminopropyl)-benzofuran (4-APB), 5-(2-aminopropyl)-benzofuran (5-APB), 6-(2-aminopropyl)-benzofuran (6-APB), 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine (5-MAPDB), 5-(2-methylaminopropyl)-benzofuran (5-MAPB), mixed dopaminergic-serotonergic amphetamines, N-alkylated analogs of mixed dopaminergic-serotonergic amphetamines, and active metabolites thereof.

14 . The prodrug of claim 12 , wherein the amino acid is chosen from the group consisting of lysine, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.

15 . A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt.

16 . The pharmaceutical composition of claim 15 , wherein said psychoactive base substance is made of 3,4-methylenedioxymethamphetamine (MDMA) or an MDMA-like substance chosen from the group consisting of 3,4-methylenedioxamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDEA), 1-(1,3-benzodioxol-5-yl)methyl-2-butanamine (MBDB), 1-(1,3-benzodioxol-5-yl)-2-aminobutane (BDB), methylone, ethylone, 2F-MDA, 5F-MDA, 6F-MDA, 5,6-methylenedioxy-2-aminoindane (MDAI), 5-iodo-2-aminoindane (5-IAI), 4-(2-aminopropyl)-benzofuran (4-APB), 5-(2-aminopropyl)-benzofuran (5-APB), 6-(2-aminopropyl)-benzofuran (6-APB), 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine (5-MAPDB), 5-(2-methylaminopropyl)-benzofuran (5-MAPB), mixed dopaminergic-serotonergic amphetamines, N-alkylated analogs of mixed dopaminergic-serotonergic amphetamines, and active metabolites thereof.

17 . The pharmaceutical composition of claim 15 , wherein said amino acid is chosen from the group consisting of lysine, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine.

18 . The pharmaceutical composition of claim 15 , wherein said pharmaceutically acceptable salt is chosen from the group consisting of sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogen-phosphate, dihydrogenphosphate, metaphosphate, pyro-phosphate, chloride, bromide, iodide, formate, acetate, propionate, decanoate, caprylate, acrylate, isobutyrate, caproate, heptanoate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, benzoate, phthalate, malate, sulfonate, phenylacetate, citrate, lactate, glycollate, tartrate, methanesulfonate, propanesulfonate, and mandelate.

19 . The pharmaceutical composition of claim 18 , wherein said pharmaceutically acceptable salt contains at least one deuteron or at least fluorine atom, including stereoisomers thereof.